Regulatory Dashboard | Navigating Rare Diseases: Considerations for the Development of Drugs and Biological Products Guidance for Industry

Rare diseases, affecting fewer than 200,000 people in the US, present unique challenges in drug development, particularly due to limited medical knowledge, unclear natural history, small patient populations, and a lack of development experience. This guidance provides comprehensive regulatory considerations for successfully developing small molecule- and biologics-based drug products for rare diseases, offering recommendations on natural history studies, nonclinical, quality, and clinical development.

The FDA’s guidance offers a flexible and comprehensive approach to developing drugs for rare diseases, acknowledging the unique challenges and encouraging early and continuous dialogue with the FDA. Ergomed, with its extensive expertise in regulatory affairs and rare disease clinical development, can provide invaluable support in implementing this guidance.


Benefit from Ergomed Group’s extensive experience in clinical research and regulatory support by exploring our detailed whitepaper. Our expertise can help you navigate the intricate landscape of rare disease drug development and make a meaningful impact on patients’ lives.

Please enter your details to get access to the resource

    This site uses cookies to personalize and customize your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

    Privacy Settings saved!
    Privacy Settings

    When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

    • wordpress_test_cookie
    • wordpress_logged_in_
    • wordpress_sec

    Decline all Services
    Accept all Services
    Secured By miniOrange